RSS Feeds
Search

Industry news

EntreMed Reports Second Quarter 2010 Financial Results

In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.

Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.

Company details

If you want to find out more about the company visit EntreMed profile.

Related reports

Market Research Reports provided by reports.iptechex.com
EntreMed, Inc. – Product Pipeline Review – Q1 2011
Mar 2011 - 79 pages - $500
First Solar Q3 2010 Results – Highest Quarterly Net Sales in the Year
Nov 2010 - 5 pages - $500
EntreMed, Inc. (ENMD) - Financial and Strategic SWOT Analysis Review
Feb 2011 - 37 pages - $125
EntreMed Inc-Therapeutic Competitors
Nov 2010 - 183 pages - $600
EntreMed, Inc. (ENMD) - Financial and Strategic SWOT Analysis Review
May 2011 - 38 pages - $125
Vestas Q3 2010 Results - Highest Order Intake in a Quarter
Oct 2010 - 5 pages - $500
APAC IT Services Quarterly Briefing, 2Q11
Aug 2011 - 22 pages - $1,895
Market Alert: 4Q10 and 2010 Global OC
Mar 2011 - 8 pages - $1,500
EntreMed Inc-Detailed Product Pipeline
Nov 2010 - 163 pages - $750
Market Share Alert: 1Q11 Global OC
Jun 2011 - 10 pages - $1,500
More Related Market Research Reports >>>

Related news

Latest News

Market Update
Financial Results for The First Half Of 2010: Programs On Track, Decrease In Operating Loss, Controlled Burn Rate And Strong Cash Position
Monsanto Projects Solid Conclusion of Fiscal Year
Pacgen Reports First Quarter Financial Results
Financial Results H1 2010
Preliminary Final Report for the year ended 30 June 2010
MESOBLAST FINANCIAL YEAR END RESULTS
EntreMed Reports Second Quarter 2010 Financial Results
Hana Biosciences Reports Second Quarter 2010 Financial Results
NuSep Investor Presentations
More news... | RSS Feed...

Most Viewed

Market Update

Preliminary Final Report for the year ended 30 June 2010

Monsanto Projects Solid Conclusion of Fiscal Year

Financial Results for The First Half Of 2010: Programs On Track, Decrease In Operating Loss, Controlled Burn Rate And Strong Cash Position

Hana Biosciences Reports Second Quarter 2010 Financial Results

Financial Results H1 2010

MESOBLAST FINANCIAL YEAR END RESULTS

Pacgen Reports First Quarter Financial Results

EntreMed Reports Second Quarter 2010 Financial Results

NuSep Investor Presentations

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us